Spondyloarthritis; IBD; extra-intestinal manifestation of IBD
Abstract :
[en] BACKGROUND: Spondyloarthritis is the most frequent extra-intestinal manifestation of IBD. AIM: To present simple strategies to identify and differentiate inflammatory joint pain in IBD patients. METHODS: A panel of Belgian gastroenterologists and rheumatologists developed seven algorithms for IBD patients with joint symptoms based on a Delphi exercise conducted between April and December 2016. Here, we focus on referral strategies for patients with chronic back pain (evidence-based strategy), large joint monoarthritis, oligo- or polyarticular arthritis or arthralgia (based on expert opinion). We also present management tools for IBD patients with acute back pain and small joint monoarthritis (Supplementary file). RESULTS: The reported algorithm for IBD patients with chronic back pain uses basic clinical criteria to identify which patients should be referred to the emergency room (spondylodiscitis), physical medicine and rehabilitation (mechanical back pain) or rheumatologist (spondyloarthritis). IBD patients with large joint monoarthritis should be referred to emergency room if septic arthritis is suspected; in other patients, blood analyses and referral to a rheumatologist for articular puncture with evacuation of synovial fluid are recommended. The analysis of synovial fluid allows for identification of non-inflammatory (e.g., osteoarthritis) and inflammatory (e.g., [pseudo]-gout, peripheral spondyloarthritis and Borrelia burgdorferi arthritis) conditions. In patients with inflammatory oligoarticular or polyarticular arthralgia, erythrocyte sedimentation rate, concomitant therapies, anti-nuclear factor and anti-double-stranded DNA antibody levels should be evaluated; in anti-tumour necrosis factor-treated patients, a drug-induced lupus-like syndrome should be considered. CONCLUSION: We propose straightforward strategies for IBD patients with joint symptoms, which are specific enough to select initial treatment and referral pattern.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Varkas, Gaëlle
RIBBENS, Clio ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Van den Bosch, Filip
Lories, Rik
Vermeire, Severine
Elewaut, Dirk
De Vos, Martine
Language :
English
Title :
Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies.
Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7:235-241.
Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239-254.
Parma A, Cometi L, Leone MC, et al. One year in review 2016: spondyloarthritis. Clin Exp Rheumatol. 2017;35:3-17.
Faustini F, Zoli A, Ferraccioli GF. Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases. Eur Rev Med Pharmacol Sci. 2009;13(Suppl 1):1-9.
Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451-471.
van Sommeren S, Janse M, Karjalainen J, et al. Extraintestinal manifestations and complications in inflammatory bowel disease: from shared genetics to shared biological pathways. Inflamm Bowel Dis. 2014;20:987-994.
Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international society (asas) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1-ii44.
Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63:535-543.
Braun J, Sieper J, Breban M, et al. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: International experience. Ann Rheum Dis. 2002;61:iii51-60.
Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388-1398.
Dougados M, Demattei C, van den Berg R, et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheumatol. 2016;68:1904-1913.
Karreman MC, Luime JJ, Hazes J, Weel A. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:631-642.
De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology. 1996;110:1696-1703.
Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. Ii. Histological aspects. J Rheumatol. 1995;22:2273-2278.
Lanna C, Ferrari MdLA, Rocha SL, Nascimento E, de Carvalho M, da Cunha AS. A cross-sectional study of 130 Brazilian patients with crohn's disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol. 2008;27:503-509.
McEniff N, Eustace S, McCarthy C, O'Malley M, O'Morain CA, Hamilton S. Asymptomatic sacroiliitis in inflammatory bowel disease assessment by computed tomography. Clin Imaging. 1995;19:258-262.
Steer S, Jones H, Hibbert J, et al. Low back pain, sacroiliitis, and the relationship with HLA-b27 in Crohn's disease. J Rheumatol. 2003;30:518-522.
Leclerc-Jacob S, Lux G, Rat AC, et al. The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther. 2014;39:957-962.
Gotler J, Amitai MM, Lidar M, Aharoni D, Flusser G, Eshed I. Utilizing mr enterography for detection of sacroiliitis in patients with inflammatory bowel disease. J Magn Reson Imaging. 2015;42:121-127.
Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 infectious diseases society of America (idsa) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61:e26-46.
Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344:363-370.
O'Shea FD, Boyle E, Salonen DC, et al. Inflammatory and degenerative sacroiliac joint disease in a primary back pain cohort. Arthritis Care Res (Hoboken). 2010;62:447-454.
Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol. 1995;34:1074-1077.
Mau W, Zeidler H, Mau R, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol. 1988;15:1109-1114.
Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-788.
van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (assert). Arthritis Rheum. 2005;52:582-591.
van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136-2146.
Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (topas). Ann Rheum Dis. 2014;73:817-823.
Sandborn W, Gasink C, Blank M, et al. O-001a multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23p40 mab, in moderate-service crohn's disease refractory to anti-tfnalpha: Uniti-1. Inflamm Bowel Dis. 2016;22(Suppl 1):S1.
Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014;73:243-246.
Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2016;76:878-881.
Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the observ-ibd cohort. Aliment Pharmacol Ther. 2018;47:485-493.
Dougados M, Paternotte S, Braun J, et al. Asas recommendations for collecting, analysing and reporting nsaid intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70:249-251.
Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:751-757.
Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-211.
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311-317.
Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64:659-663.
van Tubergen A, Heuft-Dorenbosch L, Schulpen G, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis. 2003;62:519-525.
Desforges JF, Baker DG, Schumacher HR. Acute monoarthritis. N Engl J Med. 1993;329:1013-1020.
Gladman DD. Clinical aspects of the spondyloarthropathies. Am J Med Sci. 1998;316:234-238.
Cervera R, Khamashta MA, Hughes GR. The euro-lupus project: Epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009;18:869-874.
Jeong H, Kim AY, Yoon HJ, et al. Clinical courses and predictors of outcomes in patients with monoarthritis: a retrospective study of 171 cases. Int J Rheum Dis. 2014;17:502-510.
Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA. 2007;297:1478-1488.
Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA. 1990;264:1009-1014.
Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American rheumatism association. Arthritis Rheum. 1986;29:1039-1049.
Zhang W, Doherty M, Pascual E, et al. Eular evidence based recommendations for gout. Part i: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (escisit). Ann Rheum Dis. 2006;65:1301-1311.
Schenk J, Doebis C, Küsters U, von Baehr V. Evaluation of a new multiparametric microspot array for serodiagnosis of lyme borreliosis. Clin Lab. 2015;61:1715-1725.
Schellekens GA, Visser H, De Jong B, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163.
Verbruggen G, Wittoek R, Vander Cruyssen B, Elewaut D. Morbid anatomy of 'erosive osteoarthritis' of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected joints. Ann Rheum Dis. 2010;69:862-867.
Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:654-661.
Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806-815.
Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1515-1525.
Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 1997;36:1089-1094.
Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242-251.
De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14:931-937.
De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545-R551.
